Data compiled by Redley Lamar · ChainSifter Intelligence
13Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Intensity Therapeutics, Inc. (INTS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
22Total relationships
4Distinct source URLs
11High confidence
0.794Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Intensity Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CENTRAL-LABORATORIES
CENTRAL-LABORATORIES
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
CLINICAL-TRIAL-SITES
CLINICAL-TRIAL-SITES
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
SWISS-CANCER-INSTITUTE
SWISS-CANCER-INSTITUTE
80%
In October 2024, in collaboration with the Swiss Cancer Institute, formerly the Swiss Cancer Group for Clinical Cancer Research (SAKK), we initiated and dosed our first patient in a Phase 2 study
Reciprocal relationship from ATON graph: on originally in OCI during the fiscal year. 33 Results of Operations for Fiscal 2024 Compared to Fiscal 2023 We incurred a net loss of approximately $75.4 mi…
Reciprocal relationship from GILD graph: Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false …
n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may assert that a claim that includes items o…
Reciprocal relationship from ORANY graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ORAN…
ess and monitor the product’s safety and effectiveness after commercialization. FDA may also condition approval of a drug product on the development and approval of a REMS. A REMS could include medic…
n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may assert that a claim that includes items o…
Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false …
Reciprocal relationship from SOHU graph: Reciprocal relationship from INTS graph: Reciprocal relationship from SOHU graph: Reciprocal relationship from INTS graph: Reciprocal relationship from SOHU g…
In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with…
Reciprocal relationship from MRK graph: Reciprocal relationship from INTS graph: In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT2…
Reciprocal relationship from ATON graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ATON graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ATON g…
CO-LLC
CO-LLC
62%
n 2025 compared to zero in 2024. • Insurance decreased by $0.2 million due to the favorable directors and officers insurance renewal terms obtained in 2025 compared to the prior policy year. • Legal,…
THINKEQUITY-LLC
THINKEQUITY-LLC
62%
n 2025 compared to zero in 2024. • Insurance decreased by $0.2 million due to the favorable directors and officers insurance renewal terms obtained in 2025 compared to the prior policy year. • Legal,…
Intensity Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INTS-DEBT-10308
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
INTS-DEBT-10307
Warrants outstanding: 159000
90%
xbrl warrant detail from xbrl 2023-12-31.
INTS-DEBT
Debt stack $102,000
90%
Market cache reports total debt of $102,000.
Intensity Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Intensity Therapeutics, Inc..
Intensity Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
INTS-OWNER-CORIENT-PRIVATE-WEALTH-LLC
Corient Private Wealth LLC
90%
13F overlay lists Corient Private Wealth LLC as top holder; 3 tracked holders.
Intensity Therapeutics, Inc. Extended Supply Chain Network
